Aspect Biosystems and Novo Nordisk A/S recently announced a collaboration, development, and licence agreement to develop bioprinted tissue therapeutics designed to replace, repair, or supplement biological functions inside the body with the aim of delivering a new class of truly disease-modifying treatments for diabetes and obesity.
This partnership allows Aspect and Novo Nordisk to join the proprietary bioprinting technology from Aspect with the expertise and technology that Novo Nordisk has in stem cell differentiation and cell therapy development and manufacturing.
As a result of this agreement, Aspect is providing Novo Nordisk with an exclusive, worldwide licence. The license will allow Novo Nordisk to develop up to four products, with the purpose of treating diabetes and/or obesity.In return, Aspect will receive $75 million USD in associated initial payments, plus eligibility for $650 million USD in future development, regulatory, commercial and sales milestone payments per product, as well as tiered royalties on future product sales.
This announcement demonstrates the amplified potential for medical breakthroughs and therapeutics that come with collaborative work.
Read more about the announcement here